{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T11:17:28Z","timestamp":1789903048438,"version":"4.0.1"},"reference-count":111,"publisher":"American Society for Microbiology","issue":"1","license":[{"start":{"date-parts":[[2017,2,24]],"date-time":"2017-02-24T00:00:00Z","timestamp":1487894400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Microbiol Spectr"],"published-print":{"date-parts":[[2017,2,24]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Molecular technology revolutionized the diagnosis of tuberculosis (TB) with a paradigm shift to faster, more sensitive, clinically relevant patient care. The most recent molecular leader is the GeneXpert MTB\/RIF assay (Xpert) (Cepheid, Sunnyvale, CA), which was endorsed by the World Health Organization with unprecedented speed in December 2010 as the initial diagnostic for detection of HIV-associated TB and for where high rates of drug resistance are suspected. South Africa elected to take an aggressive smear replacement approach to facilitate earlier diagnosis and treatment through the decision to implement the Xpert assay nationally in March 2011, against the backdrop of approximately 6.3 million HIV-infected individuals, one of highest global TB and HIV coinfection rates, no available implementation models, uncertainties around field performance and program costs, and lack of guidance on how to operationalize the assay into existing complex clinical algorithms. South Africa\u2019s national implementation was conducted as a phased, forecasted, and managed approach (March 2011 to September 2013), through political will and both treasury-funded and donor-funded support. Today there are 314 GeneXperts across 207 microscopy centers; over 8 million assays have been conducted, and South Africa accounts for over half the global test cartridge usage. As with any implementation of new technology, challenges were encountered, both predicted and unexpected. This chapter discusses the challenges and consequences of such large-scale implementation efforts, the opportunities for new innovations, and the need to strengthen health systems, as well as the impact of the Xpert assay on rifampin-sensitive and multidrug-resistant TB patient care that translated into global TB control as we move toward the sustainable development goals.<\/jats:p>","DOI":"10.1128\/microbiolspec.tbtb2-0040-2016","type":"journal-article","created":{"date-parts":[[2017,2,3]],"date-time":"2017-02-03T07:45:18Z","timestamp":1486107918000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":56,"title":["Impact of the GeneXpert MTB\/RIF Technology on Tuberculosis Control"],"prefix":"10.1128","volume":"5","author":[{"given":"Wendy Susan","family":"Stevens","sequence":"first","affiliation":[{"name":"Department of Molecular Medicine and Haematology, Faculty of Health Sciences, University of the Witwatersrand, and National Health Laboratory Service and National Priority Program of the National Health Laboratory Service, Johannesburg, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lesley","family":"Scott","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine and Haematology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, Gauteng, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara","family":"Noble","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine and Haematology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, Gauteng, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha","family":"Gous","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine and Haematology, Faculty of Health Sciences, University of the Witwatersrand, and National Health Laboratory Service and National Priority Program of the National Health Laboratory Service, Johannesburg, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keertan","family":"Dheda","sequence":"additional","affiliation":[{"name":"Lung Infection and Immunity Unit, Division of Pulmonology and UCT Lung Institute, Department of Medicine, University of Cape Town, Cape Town, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","unstructured":"World Health Organization. 2015. Global Tuberculosis Report . World Health Organization Geneva Switzerland."},{"key":"e_1_3_2_3_2","unstructured":"World Health Organization. 2013. Global Tuberculosis Report . World Health Organization Geneva Switzerland."},{"key":"e_1_3_2_4_2","unstructured":"World Health Organization. 2014. WHO End TB Strategy . World Health Organization Geneva Switzerland."},{"key":"e_1_3_2_5_2","doi-asserted-by":"crossref","unstructured":"Abubakar I Lipman M McHugh TD Fletcher H. 2016. Uniting to end the TB epidemic: advances in disease control from prevention to better diagnosis and treatment. BMC Med 14: 47 http:\/\/dx.doi.org\/10.1186\/s12916-016-0599-1. [PubMed]","DOI":"10.1186\/s12916-016-0599-1"},{"key":"e_1_3_2_6_2","doi-asserted-by":"crossref","unstructured":"Kranzer K Houben RM Glynn JR Bekker LG Wood R Lawn SD. 2010. Yield of HIV-associated tuberculosis during intensified case finding in resource-limited settings: a systematic review and meta-analysis. Lancet Infect Dis 10: 93\u2013102 http:\/\/dx.doi.org\/10.1016\/S1473-3099(09)70326-3.","DOI":"10.1016\/S1473-3099(09)70326-3"},{"key":"e_1_3_2_7_2","unstructured":"Apers L Mutsvangwa J Magwenzi J Chigara N Butterworth A Mason P Van der Stuyft P. 2003. A comparison of direct microscopy the concentration method and the Mycobacteria Growth Indicator Tube for the examination of sputum for acid-fast bacilli. Int J Tuberc Lung Dis 7: 376\u2013381. [PubMed]"},{"key":"e_1_3_2_8_2","doi-asserted-by":"crossref","unstructured":"Cattamanchi A Dowdy DW Davis JL Worodria W Yoo S Joloba M Matovu J Hopewell PC Huang L. 2009. Sensitivity of direct versus concentrated sputum smear microscopy in HIV-infected patients suspected of having pulmonary tuberculosis. BMC Infect Dis 9: 53 http:\/\/dx.doi.org\/10.1186\/1471-2334-9-53.","DOI":"10.1186\/1471-2334-9-53"},{"key":"e_1_3_2_9_2","doi-asserted-by":"crossref","unstructured":"Crampin AC Floyd S Mwaungulu F Black G Ndhlovu R Mwaiyeghele E Glynn JR Warndorff DK Fine PE. 2001. Comparison of two versus three smears in identifying culture-positive tuberculosis patients in a rural African setting with high HIV prevalence. Int J Tuberc Lung Dis 5: 994\u2013999. [PubMed]","DOI":"10.4314\/mmj.v13i4.10786"},{"key":"e_1_3_2_10_2","doi-asserted-by":"crossref","unstructured":"Scott CP Dos Anjos Filho L De Queiroz Mello FC Thornton CG Bishai WR Fonseca LS Kritski AL Chaisson RE Manabe YC. 2002. Comparison of C(18)-carboxypropylbetaine and standard N -acetyl- l -cysteine-NaOH processing of respiratory specimens for increasing tuberculosis smear sensitivity in Brazil. J Clin Microbiol 40: 3219\u20133222 http:\/\/dx.doi.org\/10.1128\/JCM.40.9.3219-3222.2002.","DOI":"10.1128\/JCM.40.9.3219-3222.2002"},{"key":"e_1_3_2_11_2","doi-asserted-by":"crossref","unstructured":"Selvakumar N Rahman F Garg R Rajasekaran S Mohan NS Thyagarajan K Sundaram V Santha T Frieden TR Narayanan PR. 2002. Evaluation of the phenol ammonium sulfate sedimentation smear microscopy method for diagnosis of pulmonary tuberculosis. J Clin Microbiol 40: 3017\u20133020 http:\/\/dx.doi.org\/10.1128\/JCM.40.8.3017-3020.2002.","DOI":"10.1128\/JCM.40.8.3017-3020.2002"},{"key":"e_1_3_2_12_2","doi-asserted-by":"crossref","unstructured":"Swai HF Mugusi FM Mbwambo JK. 2011. Sputum smear negative pulmonary tuberculosis: sensitivity and specificity of diagnostic algorithm. BMC Res Notes 4: 475 http:\/\/dx.doi.org\/10.1186\/1756-0500-4-475.","DOI":"10.1186\/1756-0500-4-475"},{"key":"e_1_3_2_13_2","unstructured":"World Health Organization. 2010. Policy Framework for Implementing New Tuberculosis Diagnostics . World Health Organization Geneva Switzerland."},{"key":"e_1_3_2_14_2","doi-asserted-by":"crossref","unstructured":"Anderson ST Kaforou M Brent AJ Wright VJ Banwell CM Chagaluka G Crampin AC Dockrell HM French N Hamilton MS Hibberd ML Kern F Langford PR Ling L Mlotha R Ottenhoff TH Pienaar S Pillay V Scott JA Twahir H Wilkinson RJ Coin LJ Heyderman RS Levin M Eley B ILULU Consortium KIDS TB Study Group. 2014. Diagnosis of childhood tuberculosis and host RNA expression in Africa. N Engl J Med 370: 1712\u20131723 http:\/\/dx.doi.org\/10.1056\/NEJMoa1303657.","DOI":"10.1056\/NEJMoa1303657"},{"key":"e_1_3_2_15_2","doi-asserted-by":"crossref","unstructured":"Black A. 2013. A new algorithm for the diagnosis of all forms of tuberculosis is required for South Africa. S Afr Med J 103: 355\u2013356 http:\/\/dx.doi.org\/10.7196\/samj.6896.","DOI":"10.7196\/SAMJ.6896"},{"key":"e_1_3_2_16_2","doi-asserted-by":"crossref","unstructured":"J\u00f6nsson B L\u00f6nnermark E Ridell M. 2015. Evaluation of the Cobas TaqMan MTB test for detection of Mycobacterium tuberculosis complex. Infect Dis (Lond) 47: 231\u2013236 http:\/\/dx.doi.org\/10.3109\/00365548.2014.987162. [PubMed]","DOI":"10.3109\/00365548.2014.987162"},{"key":"e_1_3_2_17_2","doi-asserted-by":"crossref","unstructured":"Lee MR Chung KP Wang HC Lin CB Yu CJ Lee JJ Hsueh PR. 2013. Evaluation of the Cobas TaqMan MTB real-time PCR assay for direct detection of Mycobacterium tuberculosis in respiratory specimens. J Med Microbiol 62: 1160\u20131164 http:\/\/dx.doi.org\/10.1099\/jmm.0.052043-0. [PubMed]","DOI":"10.1099\/jmm.0.052043-0"},{"key":"e_1_3_2_18_2","doi-asserted-by":"crossref","unstructured":"Dalovisio JR Montenegro-James S Kemmerly SA Genre CF Chambers R Greer D Pankey GA Failla DM Haydel KG Hutchinson L Lindley MF Nunez BM Praba A Eisenach KD Cooper ES. 1996. Comparison of the amplified Mycobacterium tuberculosis (MTB) direct test Amplicor MTB PCR and IS6110-PCR for detection of MTB in respiratory specimens. Clin Infect Dis 23: 1099\u20131106 discussion 1107\u20131108 http:\/\/dx.doi.org\/10.1093\/clinids\/23.5.1099.","DOI":"10.1093\/clinids\/23.5.1099"},{"key":"e_1_3_2_19_2","doi-asserted-by":"crossref","unstructured":"Wang JY Lee LN Chou CS Huang CY Wang SK Lai HC Hsueh PR Luh KT. 2004. Performance assessment of a nested-PCR assay (the RAPID BAP-MTB) and the BD ProbeTec ET system for detection of Mycobacterium tuberculosis in clinical specimens. J Clin Microbiol 42: 4599\u20134603 http:\/\/dx.doi.org\/10.1128\/JCM.42.10.4599-4603.2004.","DOI":"10.1128\/JCM.42.10.4599-4603.2004"},{"key":"e_1_3_2_20_2","doi-asserted-by":"crossref","unstructured":"Scott LE McCarthy K Gous N Nduna M Van Rie A Sanne I Venter WF Duse A Stevens W. 2011. Comparison of Xpert MTB\/RIF with other nucleic acid technologies for diagnosing pulmonary tuberculosis in a high HIV prevalence setting: a prospective study. PLoS Med 8: e1001061 http:\/\/dx.doi.org\/10.1371\/journal.pmed.1001061.","DOI":"10.1371\/journal.pmed.1001061"},{"key":"e_1_3_2_21_2","unstructured":"World Health Organization. 2008. Molecular line probe assays for rapid screening of patients at risk of multidrug-resistant tuberculosis (MDR-TB) . World Health Organization Geneva Switzerland."},{"key":"e_1_3_2_22_2","unstructured":"World Health Organization. 2010. WHO endorses new rapid tuberculosis test. A major milestone for global TB diagnosis and care. http:\/\/www.who.int\/mediacentre\/news\/releases\/2010\/tb_test_20101208\/en\/."},{"key":"e_1_3_2_23_2","doi-asserted-by":"crossref","unstructured":"Barnard M Gey van Pittius NC van Helden PD Bosman M Coetzee G Warren RM. 2012. The diagnostic performance of the GenoType MTBDRplus version 2 line probe assay is equivalent to that of the Xpert MTB\/RIF assay. J Clin Microbiol 50: 3712\u20133716 http:\/\/dx.doi.org\/10.1128\/JCM.01958-12.","DOI":"10.1128\/JCM.01958-12"},{"key":"e_1_3_2_24_2","doi-asserted-by":"crossref","unstructured":"Crudu V Stratan E Romancenco E Allerheiligen V Hillemann A Moraru N. 2012. First evaluation of an improved assay for molecular genetic detection of tuberculosis as well as rifampin and isoniazid resistances. J Clin Microbiol 50: 1264\u20131269 http:\/\/dx.doi.org\/10.1128\/JCM.05903-11.","DOI":"10.1128\/JCM.05903-11"},{"key":"e_1_3_2_25_2","doi-asserted-by":"crossref","unstructured":"Matabane MM Ismail F Strydom KA Onwuegbuna O Omar SV Ismail N. 2015. Performance evaluation of three commercial molecular assays for the detection of Mycobacterium tuberculosis from clinical specimens in a high TB-HIV-burden setting. BMC Infect Dis 15: 508 http:\/\/dx.doi.org\/10.1186\/s12879-015-1229-9.","DOI":"10.1186\/s12879-015-1229-9"},{"key":"e_1_3_2_26_2","doi-asserted-by":"crossref","unstructured":"Theron G Peter J Richardson M Barnard M Donegan S Warren R Steingart KR Dheda K. 2014. The diagnostic accuracy of the GenoType(\u00ae) MTBDRsl assay for the detection of resistance to second-line anti-tuberculosis drugs. Cochrane Database Syst Rev (10) : CD010705 10.1002\/14651858.CD010705.pub2:CD010705.","DOI":"10.1002\/14651858.CD010705.pub2"},{"key":"e_1_3_2_27_2","doi-asserted-by":"crossref","unstructured":"Brossier F Guindo D Pham A Reibel F Sougakoff W Veziris N Aubry A. 2016. Performance of the new version (v2.0) of the GenoType MTBDRsl test for detection of resistance to second-line drugs in multidrug-resistant Mycobacterium tuberculosis complex strains. J Clin Microbiol 54: 1573\u20131580 http:\/\/dx.doi.org\/10.1128\/JCM.00051-16.","DOI":"10.1128\/JCM.00051-16"},{"key":"e_1_3_2_28_2","doi-asserted-by":"crossref","unstructured":"Tagliani E Cabibbe AM Miotto P Borroni E Toro JC Mansj\u00f6 M Hoffner S Hillemann D Zalutskaya A Skrahina A Cirillo DM. 2015. Diagnostic performance of the new version (v2.0) of GenoType MTBDRsl assay for detection of resistance to fluoroquinolones and second-line injectable drugs: a multicenter study. J Clin Microbiol 53: 2961\u20132969 http:\/\/dx.doi.org\/10.1128\/JCM.01257-15.","DOI":"10.1128\/JCM.01257-15"},{"key":"e_1_3_2_29_2","unstructured":"World Health Organization. 2016. The Use of Molecular Line Probe Assays for the Detection of Resistance to Second-Line Anti-Tuberculosis Drugs . World Health Organization Geneva Switzerland."},{"key":"e_1_3_2_30_2","unstructured":"UNITAID. 2015. Tuberculosis Diagnostics Technology and Market Landscape . World Health Organization Geneva Switzerland."},{"key":"e_1_3_2_31_2","unstructured":"World Health Organization. 2011. Policy Statement: Automated Real-Time Nucleic Acid Amplification Technology for Rapid and Simultaneous Detection of Tuberculosis and Rifampicin Resistance: Xpert MTB\/RIF System . World Health Organization Geneva Switzerland."},{"key":"e_1_3_2_32_2","doi-asserted-by":"crossref","unstructured":"Lawn SD Nicol MP. 2011. Xpert\u00ae MTB\/RIF assay: development evaluation and implementation of a new rapid molecular diagnostic for tuberculosis and rifampicin resistance. Future Microbiol 6: 1067\u20131082 http:\/\/dx.doi.org\/10.2217\/fmb.11.84.","DOI":"10.2217\/fmb.11.84"},{"key":"e_1_3_2_33_2","doi-asserted-by":"crossref","unstructured":"O\u2019Grady J Bates M Chilukutu L Mzyece J Cheelo B Chilufya M Mukonda L Mumba M Tembo J Chomba M Kapata N Maeurer M Rachow A Clowes P Hoelscher M Mwaba P Zumla A. 2012. Evaluation of the Xpert MTB\/RIF assay at a tertiary care referral hospital in a setting where tuberculosis and HIV infection are highly endemic. Clin Infect Dis 55: 1171\u20131178 http:\/\/dx.doi.org\/10.1093\/cid\/cis631.","DOI":"10.1093\/cid\/cis631"},{"key":"e_1_3_2_34_2","doi-asserted-by":"crossref","unstructured":"Steingart KR Sohn H Schiller I Kloda LA Boehme CC Pai M Dendukuri N. 2013. Xpert\u00ae MTB\/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database Syst Rev (1) : CD009593 10.1002\/14651858.CD009593.pub2:CD009593.","DOI":"10.1002\/14651858.CD009593.pub2"},{"key":"e_1_3_2_35_2","doi-asserted-by":"crossref","unstructured":"Theron G Peter J van Zyl-Smit R Mishra H Streicher E Murray S Dawson R Whitelaw A Hoelscher M Sharma S Pai M Warren R Dheda K. 2011. Evaluation of the Xpert MTB\/RIF assay for the diagnosis of pulmonary tuberculosis in a high HIV prevalence setting. Am J Respir Crit Care Med 184: 132\u2013140 http:\/\/dx.doi.org\/10.1164\/rccm.201101-0056OC. [PubMed]","DOI":"10.1164\/rccm.201101-0056OC"},{"key":"e_1_3_2_36_2","doi-asserted-by":"crossref","unstructured":"Vassall A van Kampen S Sohn H Michael JS John KR den Boon S Davis JL Whitelaw A Nicol MP Gler MT Khaliqov A Zamudio C Perkins MD Boehme CC Cobelens F. 2011. Rapid diagnosis of tuberculosis with the Xpert MTB\/RIF assay in high burden countries: a cost-effectiveness analysis. PLoS Med 8: e1001120 http:\/\/dx.doi.org\/10.1371\/journal.pmed.1001120. [PubMed]","DOI":"10.1371\/journal.pmed.1001120"},{"key":"e_1_3_2_37_2","doi-asserted-by":"crossref","unstructured":"Yoon C Cattamanchi A Davis JL Worodria W den Boon S Kalema N Katagira W Kaswabuli S Miller C Andama A Albert H Nabeta P Gray C Ayakaka I Huang L. 2012. Impact of Xpert MTB\/RIF testing on tuberculosis management and outcomes in hospitalized patients in Uganda. PLoS One 7: e48599 http:\/\/dx.doi.org\/10.1371\/journal.pone.0048599.","DOI":"10.1371\/journal.pone.0048599"},{"key":"e_1_3_2_38_2","unstructured":"Stevens WS Cunningham B Cassim N Gous N Scott L. 2016. Cloud-based surveillance connectivity and distribution of the GeneXpert analyzers for diagnosis of tuberculosis (TB) and multiple-drug-resistant TB in South Africa. In Persing DH (ed) Molecular Microbiology: Diagnostic Principles and Practice 3rd ed. ASM Press Washington DC."},{"key":"e_1_3_2_39_2","unstructured":"World Health Organization. 2013. Xpert MTB\/RIF Assay for the Diagnosis of Pulmonary and Extrapulmonary TB in Adults and Children. Policy update . World Health Organization Geneva Switzerland."},{"key":"e_1_3_2_40_2","unstructured":"South African National Department of Health. 2014. National Department of Health Annual Performance Plan 2014\/15-2016\/17 . http:\/\/www.hst.org.za\/publications\/national-department-health-annual-performance-plan-201415-201617."},{"key":"e_1_3_2_41_2","unstructured":"Directorate Drug-Resistant TB TB and HIV. 2011. Management of Drug-Resistant Tuberculosis: Policy Guidelines . http:\/\/www.hst.org.za\/publications\/management-drug-resistant-tuberculosis-policy-guidelines."},{"key":"e_1_3_2_42_2","doi-asserted-by":"crossref","unstructured":"Nhu NT Ha DT Anh ND Thu DD Duong TN Quang ND Lan NT Quyet TV Tuyen NT Ha VT Giang DC Dung NH Wolbers M Farrar J Caws M. 2013. Evaluation of Xpert MTB\/RIF and MODS assay for the diagnosis of pediatric tuberculosis. BMC Infect Dis 13: 31 http:\/\/dx.doi.org\/10.1186\/1471-2334-13-31. [PubMed]","DOI":"10.1186\/1471-2334-13-31"},{"key":"e_1_3_2_43_2","doi-asserted-by":"crossref","unstructured":"Stevens WS Marshall TM. 2010. Challenges in implementing HIV load testing in South Africa. J Infect Dis 201 (Suppl 1) : S78\u2013S84 http:\/\/dx.doi.org\/10.1086\/650383.","DOI":"10.1086\/650383"},{"key":"e_1_3_2_44_2","doi-asserted-by":"crossref","unstructured":"Qin ZZ Pai M Van Gemert W Sahu S Ghiasi M Creswell J. 2015. How is Xpert MTB\/RIF being implemented in 22 high tuberculosis burden countries? Eur Respir J 45: 549\u2013554 http:\/\/dx.doi.org\/10.1183\/09031936.00147714. [PubMed]","DOI":"10.1183\/09031936.00147714"},{"key":"e_1_3_2_45_2","unstructured":"UNAIDS. 2013. South Africa: HIV and AIDS estimates 2013. http:\/\/www.unaids.org\/en\/regionscountries\/countries\/southafrica."},{"key":"e_1_3_2_46_2","doi-asserted-by":"crossref","unstructured":"Nicol MP. 2013. Xpert MTB\/RIF: monitoring response to tuberculosis treatment. Lancet Respir Med 1: 427\u2013428 http:\/\/dx.doi.org\/10.1016\/S2213-2600(13)70133-4.","DOI":"10.1016\/S2213-2600(13)70133-4"},{"key":"e_1_3_2_47_2","doi-asserted-by":"crossref","unstructured":"Schnippel K Meyer-Rath G Long L Stevens WS Sanne I Rosen S. 2013. Diagnosing Xpert MTB\/RIF negative TB: impact and cost of alternative algorithms for South Africa. S Afr Med J 103: 101\u2013106. [PubMed]","DOI":"10.7196\/SAMJ.6182"},{"key":"e_1_3_2_48_2","unstructured":"South African National AIDS Council. 2016. South African HIV and TB Investment Case Phase 1 Reference Report . Department of Health South Africa."},{"key":"e_1_3_2_49_2","unstructured":"National Health Laboratory Service. 2014. GeneXpert MTB\/RIF progress report to the National Department of Health. http:\/\/www.nhls.ac.za\/assets\/files\/GeneXpert%20Progress%20Report%20July%202014_Final.pdf."},{"key":"e_1_3_2_50_2","doi-asserted-by":"crossref","unstructured":"Churchyard GJ Stevens WS Mametja LD McCarthy KM Chihota V Nicol MP Erasmus LK Ndjeka NO Mvusi L Vassall A Sinanovic E Cox HS Dye C Grant AD Fielding KL. 2015. Xpert MTB\/RIF versus sputum microscopy as the initial diagnostic test for tuberculosis: a cluster-randomised trial embedded in South African roll-out of Xpert MTB\/RIF. Lancet Glob Health 3: e450\u2013e457 http:\/\/dx.doi.org\/10.1016\/S2214-109X(15)00100-X. doi:10.1016\/S2214-109X(15)00100-X.","DOI":"10.1016\/S2214-109X(15)00100-X"},{"key":"e_1_3_2_51_2","doi-asserted-by":"crossref","unstructured":"Houben RM Lalli M Sumner T Hamilton M Pedrazzoli D Bonsu F Hippner P Pillay Y Kimerling M Ahmedov S Pretorius C White RG. 2016. TIME Impact: a new user-friendly tuberculosis (TB) model to inform TB policy decisions. BMC Med 14: 56 http:\/\/dx.doi.org\/10.1186\/s12916-016-0608-4. doi:10.1186\/s12916-016-0608-4.","DOI":"10.1186\/s12916-016-0608-4"},{"key":"e_1_3_2_52_2","doi-asserted-by":"crossref","unstructured":"Basu S Andrews JR Poolman EM Gandhi NR Shah NS Moll A Moodley P Galvani AP Friedland GH. 2007. Prevention of nosocomial transmission of extensively drug-resistant tuberculosis in rural South African district hospitals: an epidemiological modelling study. Lancet 370: 1500\u20131507 http:\/\/dx.doi.org\/10.1016\/S0140-6736(07)61636-5.","DOI":"10.1016\/S0140-6736(07)61636-5"},{"key":"e_1_3_2_53_2","doi-asserted-by":"crossref","unstructured":"Menzies NA Cohen T Lin HH Murray M Salomon JA. 2012. Population health impact and cost-effectiveness of tuberculosis diagnosis with Xpert MTB\/RIF: a dynamic simulation and economic evaluation. PLoS Med 9: e1001347 http:\/\/dx.doi.org\/10.1371\/journal.pmed.1001347.","DOI":"10.1371\/journal.pmed.1001347"},{"key":"e_1_3_2_54_2","doi-asserted-by":"crossref","unstructured":"Uplekar M. 2015. Implementing the End TB Strategy: well begun will be half done. Indian J Tuberc 62: 61\u201363 http:\/\/dx.doi.org\/10.1016\/j.ijtb.2015.03.001.","DOI":"10.1016\/j.ijtb.2015.03.001"},{"key":"e_1_3_2_55_2","doi-asserted-by":"crossref","unstructured":"Rufai SB Kumar P Singh A Prajapati S Balooni V Singh S. 2014. Comparison of Xpert MTB\/RIF with line probe assay for detection of rifampin-monoresistant Mycobacterium tuberculosis . J Clin Microbiol 52: 1846\u20131852 http:\/\/dx.doi.org\/10.1128\/JCM.03005-13.","DOI":"10.1128\/JCM.03005-13"},{"key":"e_1_3_2_56_2","doi-asserted-by":"crossref","unstructured":"Sanchez-Padilla E Merker M Beckert P Jochims F Dlamini T Kahn P Bonnet M Niemann S. 2015. Detection of drug-resistant tuberculosis by Xpert MTB\/RIF in Swaziland. N Engl J Med 372: 1181\u20131182 http:\/\/dx.doi.org\/10.1056\/NEJMc1413930.","DOI":"10.1056\/NEJMc1413930"},{"key":"e_1_3_2_57_2","doi-asserted-by":"crossref","unstructured":"Theron G Jenkins HE Cobelens F Abubakar I Khan AJ Cohen T Dowdy DW. 2015. Data for action: collection and use of local data to end tuberculosis. Lancet 386: 2324\u20132333 http:\/\/dx.doi.org\/10.1016\/S0140-6736(15)00321-9.","DOI":"10.1016\/S0140-6736(15)00321-9"},{"key":"e_1_3_2_58_2","doi-asserted-by":"crossref","unstructured":"Scott L Albert H Gilpin C Alexander H DeGruy K Stevens W. 2014. Multicenter feasibility study to assess external quality assessment panels for Xpert MTB\/RIF assay in South Africa. J Clin Microbiol 52: 2493\u20132499 http:\/\/dx.doi.org\/10.1128\/JCM.03533-13.","DOI":"10.1128\/JCM.03533-13"},{"key":"e_1_3_2_59_2","doi-asserted-by":"crossref","unstructured":"Scott LE Gous N Cunningham BE Kana BD Perovic O Erasmus L Coetzee GJ Koornhof H Stevens W. 2011. Dried culture spots for Xpert MTB\/RIF external quality assessment: results of a phase 1 pilot study in South Africa. J Clin Microbiol 49: 4356\u20134360 http:\/\/dx.doi.org\/10.1128\/JCM.05167-11.","DOI":"10.1128\/JCM.05167-11"},{"key":"e_1_3_2_60_2","doi-asserted-by":"crossref","unstructured":"Garnett GP Cousens S Hallett TB Steketee R Walker N. 2011. Mathematical models in the evaluation of health programmes. Lancet 378: 515\u2013525 http:\/\/dx.doi.org\/10.1016\/S0140-6736(10)61505-X.","DOI":"10.1016\/S0140-6736(10)61505-X"},{"key":"e_1_3_2_61_2","doi-asserted-by":"crossref","unstructured":"Knight GM Dharan NJ Fox GJ Stennis N Zwerling A Khurana R Dowdy DW. 2016. Bridging the gap between evidence and policy for infectious diseases: how models can aid public health decision-making. Int J Infect Dis 42: 17\u201323 http:\/\/dx.doi.org\/10.1016\/j.ijid.2015.10.024.","DOI":"10.1016\/j.ijid.2015.10.024"},{"key":"e_1_3_2_62_2","doi-asserted-by":"crossref","unstructured":"Langley I Lin HH Egwaga S Doulla B Ku CC Murray M Cohen T Squire SB. 2014. Assessment of the patient health system and population effects of Xpert MTB\/RIF and alternative diagnostics for tuberculosis in Tanzania: an integrated modelling approach. Lancet Glob Health 2: e581\u2013e591 http:\/\/dx.doi.org\/10.1016\/S2214-109X(14)70291-8.","DOI":"10.1016\/S2214-109X(14)70291-8"},{"key":"e_1_3_2_63_2","doi-asserted-by":"crossref","unstructured":"Dheda K Theron G Welte A. 2014. Cost-effectiveness of Xpert MTB\/RIF and investing in health care in Africa. Lancet Glob Health 2: e554\u2013e556 http:\/\/dx.doi.org\/10.1016\/S2214-109X(14)70305-5.","DOI":"10.1016\/S2214-109X(14)70305-5"},{"key":"e_1_3_2_64_2","doi-asserted-by":"crossref","unstructured":"Dowdy DW Houben R Cohen T Pai M Cobelens F Vassall A Menzies NA Gomez GB Langley I Squire SB White R TB MAC meeting participants. 2014. Impact and cost-effectiveness of current and future tuberculosis diagnostics: the contribution of modelling. Int J Tuberc Lung Dis 18: 1012\u20131018 http:\/\/dx.doi.org\/10.5588\/ijtld.13.0851.","DOI":"10.5588\/ijtld.13.0851"},{"key":"e_1_3_2_65_2","unstructured":"World Health Organization. 2014. WHO Monitoring of Xpert MTB\/RIF Rollout . World Health Organization Geneva Switzerland."},{"key":"e_1_3_2_66_2","doi-asserted-by":"crossref","unstructured":"Moore DA. 2016. What can we offer to 3 million MDRTB household contacts in 2016? BMC Med 14: 64 http:\/\/dx.doi.org\/10.1186\/s12916-016-0610-x.","DOI":"10.1186\/s12916-016-0610-x"},{"key":"e_1_3_2_67_2","doi-asserted-by":"crossref","unstructured":"Witney AA Cosgrove CA Arnold A Hinds J Stoker NG Butcher PD. 2016. Clinical use of whole genome sequencing for Mycobacterium tuberculosis . BMC Med 14: 46 http:\/\/dx.doi.org\/10.1186\/s12916-016-0598-2.","DOI":"10.1186\/s12916-016-0598-2"},{"key":"e_1_3_2_68_2","unstructured":"Scott L Schnippel K Ncayiyana J Berrie L Berhanu R Van Rie A. 2015. The use of national Xpert MTB\/RIF\u2019s cycle threshold (Ct) as an audit indicator for program and laboratory performance. 46th Union World Conference on Lung Health. Cape Town South Africa. 2\u20136 December 2015."},{"key":"e_1_3_2_69_2","doi-asserted-by":"crossref","unstructured":"Bratton DJ Nunn AJ. 2011. Alternative approaches to tuberculosis treatment evaluation: the role of pragmatic trials. Int J Tuberc Lung Dis 15: 440\u2013446 http:\/\/dx.doi.org\/10.5588\/ijtld.10.0732.","DOI":"10.5588\/ijtld.10.0732"},{"key":"e_1_3_2_70_2","doi-asserted-by":"crossref","unstructured":"Luoto J Maglione MA Johnsen B Chang C Higgs ES Perry T Shekelle PG. 2013. A comparison of frameworks evaluating evidence for global health interventions. PLoS Med 10: e1001469 http:\/\/dx.doi.org\/10.1371\/journal.pmed.1001469.","DOI":"10.1371\/journal.pmed.1001469"},{"key":"e_1_3_2_71_2","doi-asserted-by":"crossref","unstructured":"Theron G Peter J Dowdy D Langley I Squire SB Dheda K. 2014. Do high rates of empirical treatment undermine the potential effect of new diagnostic tests for tuberculosis in high-burden settings? Lancet Infect Dis 14: 527\u2013532 http:\/\/dx.doi.org\/10.1016\/S1473-3099(13)70360-8.","DOI":"10.1016\/S1473-3099(13)70360-8"},{"key":"e_1_3_2_72_2","doi-asserted-by":"crossref","unstructured":"Dheda K Barry CE III Maartens G. 2016. Tuberculosis. Lancet 387: 1211\u20131226 http:\/\/dx.doi.org\/10.1016\/S0140-6736(15)00151-8.","DOI":"10.1016\/S0140-6736(15)00151-8"},{"key":"e_1_3_2_73_2","unstructured":"Luca Di Tanna G Theron G McCarthy K Cox H Mupfumil L Sohn A Weyer K Zijenah L Mason P Hoelscher M Clowes P Mangu C Chanda D Pym A Mwaba P Khaki AR Cobelens F Nicol K Dheda K Churchyard G Fielding K Metcalfe J. 2015. The effect of nucleic acid amplification assays on patient important outcomes in routine care settings: meta-analysis of individual participant data. 46th Union World Conference on Lung Health. Cape Town South Africa. 2\u20136 December 2015."},{"key":"e_1_3_2_74_2","doi-asserted-by":"crossref","unstructured":"Cox H McDermid C. 2008. XDR tuberculosis can be cured with aggressive treatment. Lancet 372: 1363\u20131365 http:\/\/dx.doi.org\/10.1016\/S0140-6736(08)61205-2.","DOI":"10.1016\/S0140-6736(08)61205-2"},{"key":"e_1_3_2_75_2","doi-asserted-by":"crossref","unstructured":"Mupfumi L Makamure B Chirehwa M Sagonda T Zinyowera S Mason P Metcalfe JZ Mutetwa R. 2014. Impact of Xpert MTB\/RIF on antiretroviral therapy-associated tuberculosis and mortality: a pragmatic randomized controlled trial. Open Forum Infect Dis 1: ofu038 http:\/\/dx.doi.org\/10.1093\/ofid\/ofu038.","DOI":"10.1093\/ofid\/ofu038"},{"key":"e_1_3_2_76_2","doi-asserted-by":"crossref","unstructured":"Theron G Zijenah L Chanda D Clowes P Rachow A Lesosky M Bara W Mungofa S Pai M Hoelscher M Dowdy D Pym A Mwaba P Mason P Peter J Dheda K. 2013. Feasibility accuracy and clinical effect of point-of-care Xpert MTB\/RIF testing for tuberculosis in primary-care settings in Africa: a multicentre randomised controlled trial. Lancet 383: 424\u2013435 10.1016\/S0140-6736(13)62073-5.","DOI":"10.1016\/S0140-6736(13)62073-5"},{"key":"e_1_3_2_77_2","unstructured":"World Health Organization. 2014. Global Tuberculosis Report . World Health Organization Geneva Switzerland."},{"key":"e_1_3_2_78_2","doi-asserted-by":"crossref","unstructured":"Stagg HR White PJ Rieksti\u0146a V C\u012brule A \u0160\u0137enders \u0122 Leimane V Kuksa L Dravniece G Brown J Jackson C. 2016. Decreased time to treatment initiation for multidrug-resistant tuberculosis patients after use of Xpert MTB\/RIF test Latvia. Emerg Infect Dis 22: 482\u2013490 http:\/\/dx.doi.org\/10.3201\/eid2203.151227.","DOI":"10.3201\/eid2203.151227"},{"key":"e_1_3_2_79_2","doi-asserted-by":"crossref","unstructured":"van Kampen SC Susanto NH Simon S Astiti SD Chandra R Burhan E Farid MN Chittenden K Mustikawati DE Alisjahbana B. 2015. Effects of introducing Xpert MTB\/RIF on diagnosis and treatment of drug-resistant tuberculosis patients in Indonesia: a pre-post intervention study. PLoS One 10: e0123536 http:\/\/dx.doi.org\/10.1371\/journal.pone.0123536.","DOI":"10.1371\/journal.pone.0123536"},{"key":"e_1_3_2_80_2","doi-asserted-by":"crossref","unstructured":"Cox HS Daniels JF Muller O Nicol MP Cox V van Cutsem G Moyo S De Azevedo V Hughes J. 2015. Impact of decentralized care and the Xpert MTB\/RIF test on rifampicin-resistant tuberculosis treatment initiation in Khayelitsha South Africa. Open Forum Infect Dis 2: ofv014 http:\/\/dx.doi.org\/10.1093\/ofid\/ofv014.","DOI":"10.1093\/ofid\/ofv014"},{"key":"e_1_3_2_81_2","doi-asserted-by":"crossref","unstructured":"Sachdeva KS Raizada N Gupta RS Nair SA Denkinger C Paramasivan CN Kulsange S Thakur R Dewan P Boehme C Arinaminpathy N. 2015. The potential impact of up-front drug sensitivity testing on India\u2019s epidemic of multi-drug resistant tuberculosis. PLoS One 10: e0131438 http:\/\/dx.doi.org\/10.1371\/journal.pone.0131438.","DOI":"10.1371\/journal.pone.0131438"},{"key":"e_1_3_2_82_2","doi-asserted-by":"crossref","unstructured":"Salje H Andrews JR Deo S Satyanarayana S Sun AY Pai M Dowdy DW. 2014. The importance of implementation strategy in scaling up Xpert MTB\/RIF for diagnosis of tuberculosis in the Indian health-care system: a transmission model. PLoS Med 11: e1001674 http:\/\/dx.doi.org\/10.1371\/journal.pmed.1001674.","DOI":"10.1371\/journal.pmed.1001674"},{"key":"e_1_3_2_83_2","unstructured":"Singla N Singla R Fernandes S Behera D. 2009. Post treatment sequelae of multi-drug resistant tuberculosis patients. Indian J Tuberc 56: 206\u2013212. [PubMed]"},{"key":"e_1_3_2_84_2","doi-asserted-by":"crossref","unstructured":"Dlamini-Mvelase NR Werner L Phili R Cele LP Mlisana KP. 2014. Effects of introducing Xpert MTB\/RIF test on multi-drug resistant tuberculosis diagnosis in KwaZulu-Natal South Africa. BMC Infect Dis 14: 442 http:\/\/dx.doi.org\/10.1186\/1471-2334-14-442.","DOI":"10.1186\/1471-2334-14-442"},{"key":"e_1_3_2_85_2","unstructured":"UNITAID. 2014. Tuberculosis diagnostic technology landscape . World Health Organization Geneva Switzerland. http:\/\/unitaid.org\/images\/marketdynamics\/publications\/UNITAID_TB_Diagnostics_Landscape_3rd-edition.pdf."},{"key":"e_1_3_2_86_2","unstructured":"World Health Organization. 2016. WHO Treatment Guidelines for Drug-Resistant Tuberculosis: 2016 Update . World Health Organization Geneva Switzerland."},{"key":"e_1_3_2_87_2","doi-asserted-by":"crossref","unstructured":"Hanrahan CF Haguma P Ochom E Kinera I Cobelens F Cattamanchi A Davis L Katamba A Dowdy D. 2016. Implementation of Xpert MTB\/RIF in Uganda: missed opportunities to improve diagnosis of tuberculosis. Open Forum Infect Dis 3: ofw068 http:\/\/dx.doi.org\/10.1093\/ofid\/ofw068.","DOI":"10.1093\/ofid\/ofw068"},{"key":"e_1_3_2_88_2","doi-asserted-by":"crossref","unstructured":"Opota O Senn L Prod\u2019hom G Mazza-Stalder J Tissot F Greub G Jaton K. 2016. Added value of molecular assay Xpert MTB\/RIF compared to sputum smear microscopy to assess the risk of tuberculosis transmission in a low-prevalence country. Clin Microbiol Infect 22: 613\u2013619 10.1016\/j.cmi.2016.04.010. [PubMed]","DOI":"10.1016\/j.cmi.2016.04.010"},{"key":"e_1_3_2_89_2","doi-asserted-by":"crossref","unstructured":"Mbonze NB Tabala M Wenzi LK Bakoko B Brouwer M Creswell J Van Rie A Behets F Yotebieng M. 2016. Xpert \u00ae MTB\/RIF for smear-negative presumptive TB: impact on case notification in DR Congo. Int J Tuberc Lung Dis 20: 240\u2013246 http:\/\/dx.doi.org\/10.5588\/ijtld.15.0177.","DOI":"10.5588\/ijtld.15.0177"},{"key":"e_1_3_2_90_2","doi-asserted-by":"crossref","unstructured":"Lorent N Kong C Kim T Sam S Thai S Colebunders R Rigouts L Lynen L. 2015. Systematic screening for drug-resistant tuberculosis with Xpert \u00ae MTB\/RIF in a referral hospital in Cambodia. Int J Tuberc Lung Dis 19: 1528\u20131535 http:\/\/dx.doi.org\/10.5588\/ijtld.14.0956.","DOI":"10.5588\/ijtld.14.0956"},{"key":"e_1_3_2_91_2","doi-asserted-by":"crossref","unstructured":"Schumacher SG Thangakunam B Denkinger CM Oliver AA Shakti KB Qin ZZ Michael JS Luo R Pai M Christopher DJ. 2015. Impact of point-of-care implementation of Xpert \u00ae MTB\/RIF: product vs. process innovation. Int J Tuberc Lung Dis 19: 1084\u20131090 http:\/\/dx.doi.org\/10.5588\/ijtld.15.0120.","DOI":"10.5588\/ijtld.15.0120"},{"key":"e_1_3_2_92_2","doi-asserted-by":"crossref","unstructured":"van Kampen SC Tursynbayeva A Koptleuova A Murzabekova Z Bigalieva L Aubakirova M Pak S van den Hof S. 2015. Effect of introducing Xpert MTB\/RIF to test and treat individuals at risk of multidrug-resistant tuberculosis in Kazakhstan: a prospective cohort study. PLoS One 10: e0132514 http:\/\/dx.doi.org\/10.1371\/journal.pone.0132514. [Erratum 10: e0136368. doi:10.1371\/journal.pone.0136368.]","DOI":"10.1371\/journal.pone.0132514"},{"key":"e_1_3_2_93_2","doi-asserted-by":"crossref","unstructured":"Hanrahan CF Clouse K Bassett J Mutunga L Selibas K Stevens W Scott L Sanne I Van Rie A. 2015. The patient impact of point-of-care vs. laboratory placement of Xpert \u00ae MTB\/RIF. Int J Tuberc Lung Dis 19: 811\u2013816 http:\/\/dx.doi.org\/10.5588\/ijtld.15.0013.","DOI":"10.5588\/ijtld.15.0013"},{"key":"e_1_3_2_94_2","doi-asserted-by":"crossref","unstructured":"Manabe YC Zawedde-Muyanja S Burnett SM Mugabe F Naikoba S Coutinho A. 2015. Rapid improvement in passive tuberculosis case detection and tuberculosis treatment outcomes after implementation of a bundled laboratory diagnostic and on-site training intervention targeting mid-level providers. Open Forum Infect Dis 2: ofv030 http:\/\/dx.doi.org\/10.1093\/ofid\/ofv030.","DOI":"10.1093\/ofid\/ofv030"},{"key":"e_1_3_2_95_2","doi-asserted-by":"crossref","unstructured":"Sachdeva KS Raizada N Sreenivas A Van\u2019t Hoog AH van den Hof S Dewan PK Thakur R Gupta RS Kulsange S Vadera B Babre A Gray C Parmar M Ghedia M Ramachandran R Alavadi U Arinaminpathy N Denkinger C Boehme C Paramasivan CN. 2015. Use of Xpert MTB\/RIF in decentralized public health settings and its effect on pulmonary TB and DR-TB case finding in India. PLoS One 10: e0126065 http:\/\/dx.doi.org\/10.1371\/journal.pone.0126065.","DOI":"10.1371\/journal.pone.0126065"},{"key":"e_1_3_2_96_2","doi-asserted-by":"crossref","unstructured":"Trajman A Durovni B Saraceni V Menezes A Cordeiro-Santos M Cobelens F Van den Hof S. 2015. Impact on patients\u2019 treatment outcomes of XpertMTB\/RIF implementation for the diagnosis of tuberculosis: follow-up of a stepped-wedge randomized clinical trial. PLoS One 10: e0123252 http:\/\/dx.doi.org\/10.1371\/journal.pone.0123252. [Erratum 11: e0156471. doi:10.1371\/journal.pone.0156471.]","DOI":"10.1371\/journal.pone.0123252"},{"key":"e_1_3_2_97_2","doi-asserted-by":"crossref","unstructured":"Creswell J Rai B Wali R Sudrungrot S Adhikari LM Pant R Pyakurel S Uranw D Codlin AJ. 2015. Introducing new tuberculosis diagnostics: the impact of Xpert \u00ae MTB\/RIF testing on case notifications in Nepal. Int J Tuberc Lung Dis 19: 545\u2013551 http:\/\/dx.doi.org\/10.5588\/ijtld.14.0775.","DOI":"10.5588\/ijtld.14.0775"},{"key":"e_1_3_2_98_2","doi-asserted-by":"crossref","unstructured":"Van Den Handel T Hampton KH Sanne I Stevens W Crous R Van Rie A. 2015. The impact of Xpert \u00ae MTB\/RIF in sparsely populated rural settings. Int J Tuberc Lung Dis 19: 392\u2013398 http:\/\/dx.doi.org\/10.5588\/ijtld.14.0653.","DOI":"10.5588\/ijtld.14.0653"},{"key":"e_1_3_2_99_2","doi-asserted-by":"crossref","unstructured":"Alvarez GG Van Dyk DD Desjardins M Yasseen AS III Aaron SD Cameron DW Obed N Baikie M Pakhale S Denkinger CM Sohn H Pai M. 2015. The feasibility accuracy and impact of Xpert MTB\/RIF testing in a remote aboriginal community in Canada. Chest 148: 767\u2013773 http:\/\/dx.doi.org\/10.1378\/chest.14-2948.","DOI":"10.1378\/chest.14-2948"},{"key":"e_1_3_2_100_2","doi-asserted-by":"crossref","unstructured":"Moyenga I Roggi A Sulis G Diande S Tamboura D Tagliani E Castelli F Matteelli A. 2015. The impact of Xpert \u00ae MTB\/RIF depends on service coordination: experience in Burkina Faso. Int J Tuberc Lung Dis 19: 285\u2013287 http:\/\/dx.doi.org\/10.5588\/ijtld.14.0629.","DOI":"10.5588\/ijtld.14.0629"},{"key":"e_1_3_2_101_2","doi-asserted-by":"crossref","unstructured":"Durovni B Saraceni V van den Hof S Trajman A Cordeiro-Santos M Cavalcante S Menezes A Cobelens F. 2014. Impact of replacing smear microscopy with Xpert MTB\/RIF for diagnosing tuberculosis in Brazil: a stepped-wedge cluster-randomized trial. PLoS Med 11: e1001766 http:\/\/dx.doi.org\/10.1371\/journal.pmed.1001766. [Erratum 12: e1001928. doi:10.1371\/journal.pmed.1001928.]","DOI":"10.1371\/journal.pmed.1001766"},{"key":"e_1_3_2_102_2","doi-asserted-by":"crossref","unstructured":"Cox HS Mbhele S Mohess N Whitelaw A Muller O Zemanay W Little F Azevedo V Simpson J Boehme CC Nicol MP. 2014. Impact of Xpert MTB\/RIF for TB diagnosis in a primary care clinic with high TB and HIV prevalence in South Africa: a pragmatic randomised trial. PLoS Med 11: e1001760 http:\/\/dx.doi.org\/10.1371\/journal.pmed.1001760.","DOI":"10.1371\/journal.pmed.1001760"},{"key":"e_1_3_2_103_2","doi-asserted-by":"crossref","unstructured":"Chaisson LH Roemer M Cantu D Haller B Millman AJ Cattamanchi A Davis JL. 2014. Impact of GeneXpert MTB\/RIF assay on triage of respiratory isolation rooms for inpatients with presumed tuberculosis: a hypothetical trial. Clin Infect Dis 59: 1353\u20131360 http:\/\/dx.doi.org\/10.1093\/cid\/ciu620.","DOI":"10.1093\/cid\/ciu620"},{"key":"e_1_3_2_104_2","doi-asserted-by":"crossref","unstructured":"Davis JL Kawamura LM Chaisson LH Grinsdale J Benhammou J Ho C Babst A Banouvong H Metcalfe JZ Pandori M Hopewell PC Cattamanchi A. 2014. Impact of GeneXpert MTB\/RIF on patients and tuberculosis programs in a low-burden setting: a hypothetical trial. Am J Respir Crit Care Med 189: 1551\u20131559 http:\/\/dx.doi.org\/10.1164\/rccm.201311-1974OC.","DOI":"10.1164\/rccm.201311-1974OC"},{"key":"e_1_3_2_105_2","doi-asserted-by":"crossref","unstructured":"Ramirez HL Garc\u00eda-Clemente MM Alvarez-\u00c1lvarez C Palacio-Gutierrez JJ Pando-Sandoval A Gagatek S Arias-Guill\u00e9n M Quezada-Loaiza CA Casan-Clar\u00e1 P. 2014. Impact of the Xpert \u00ae MTB\/RIF molecular test on the late diagnosis of pulmonary tuberculosis. Int J Tuberc Lung Dis 18: 435\u2013437 http:\/\/dx.doi.org\/10.5588\/ijtld.13.0747.","DOI":"10.5588\/ijtld.13.0747"},{"key":"e_1_3_2_106_2","doi-asserted-by":"crossref","unstructured":"Balcha TT Stureg\u00e5rd E Winqvist N Skogmar S Reepalu A Jemal ZH Tibesso G Sch\u00f6n T Bj\u00f6rkman P. 2014. Intensified tuberculosis case-finding in HIV-positive adults managed at Ethiopian health centers: diagnostic yield of Xpert MTB\/RIF compared with smear microscopy and liquid culture. PLoS One 9: e85478 http:\/\/dx.doi.org\/10.1371\/journal.pone.0085478.","DOI":"10.1371\/journal.pone.0085478"},{"key":"e_1_3_2_107_2","doi-asserted-by":"crossref","unstructured":"Omrani AS Al-Otaibi MF Al-Ateah SM Al-Onazi FM Baig K El-Khizzi NA Albarrak AM. 2014. GeneXpert MTB\/RIF testing in the management of patients with active tuberculosis: a real life experience from Saudi Arabia. Infect Chemother 46: 30\u201334 http:\/\/dx.doi.org\/10.3947\/ic.2014.46.1.30.","DOI":"10.3947\/ic.2014.46.1.30"},{"key":"e_1_3_2_108_2","doi-asserted-by":"crossref","unstructured":"Sohn H Aero AD Menzies D Behr M Schwartzman K Alvarez GG Dan A McIntosh F Pai M Denkinger CM. 2014. Xpert MTB\/RIF testing in a low tuberculosis incidence high-resource setting: limitations in accuracy and clinical impact. Clin Infect Dis 58: 970\u2013976 http:\/\/dx.doi.org\/10.1093\/cid\/ciu022.","DOI":"10.1093\/cid\/ciu022"},{"key":"e_1_3_2_109_2","doi-asserted-by":"crossref","unstructured":"Al-Darraji HA Abd Razak H Ng KP Altice FL Kamarulzaman A. 2013. The diagnostic performance of a single GeneXpert MTB\/RIF assay in an intensified tuberculosis case finding survey among HIV-infected prisoners in Malaysia. PLoS One 8: e73717 http:\/\/dx.doi.org\/10.1371\/journal.pone.0073717.","DOI":"10.1371\/journal.pone.0073717"},{"key":"e_1_3_2_110_2","doi-asserted-by":"crossref","unstructured":"Theron G Peter J Meldau R Khalfey H Gina P Matinyena B Lenders L Calligaro G Allwood B Symons G Govender U Setshedi M Dheda K. 2013. Accuracy and impact of Xpert MTB\/RIF for the diagnosis of smear-negative or sputum-scarce tuberculosis using bronchoalveolar lavage fluid. Thorax 68: 1043\u20131051 http:\/\/dx.doi.org\/10.1136\/thoraxjnl-2013-203485.","DOI":"10.1136\/thoraxjnl-2013-203485"},{"key":"e_1_3_2_111_2","doi-asserted-by":"crossref","unstructured":"Hanrahan CF Selibas K Deery CB Dansey H Clouse K Bassett J Scott L Stevens W Sanne I Van Rie A. 2013. Time to treatment and patient outcomes among TB suspects screened by a single point-of-care Xpert MTB\/RIF at a primary care clinic in Johannesburg South Africa. PLoS One 8: e65421 http:\/\/dx.doi.org\/10.1371\/journal.pone.0065421.","DOI":"10.1371\/journal.pone.0065421"},{"key":"e_1_3_2_112_2","doi-asserted-by":"crossref","unstructured":"Calligaro GL Zijenah LS Peter JG Theron G Buser V McNerney R Bara W Bandason T Govender U Tomasicchio M Smith L Mayosi BM Dheda K. 2017. Effect of new tuberculosis diagnostic technologies on community-based intensified case finding: a multicentre randomised controlled trial. Lancet Infect Dis (epub ahead of print) doi:10.1016\/S1473-3099(16)30384-X.","DOI":"10.1016\/S1473-3099(16)30384-X"}],"container-title":["Microbiology Spectrum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/microbiolspec.TBTB2-0040-2016","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/microbiolspec.TBTB2-0040-2016","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,8]],"date-time":"2022-03-08T01:22:55Z","timestamp":1646702575000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/microbiolspec.TBTB2-0040-2016"}},"subtitle":[],"editor":[{"given":"William R.","family":"Jacobs Jr.","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]},{"given":"Helen","family":"McShane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]},{"given":"Valerie","family":"Mizrahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]},{"given":"Ian M.","family":"Orme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2017,2,24]]},"references-count":111,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,2,24]]}},"alternative-id":["10.1128\/microbiolspec.TBTB2-0040-2016"],"URL":"https:\/\/doi.org\/10.1128\/microbiolspec.tbtb2-0040-2016","relation":{},"ISSN":["2165-0497"],"issn-type":[{"value":"2165-0497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,24]]},"assertion":[{"value":"2016-07-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-02-03","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"5.1.17"}}